125 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
liabilities (including $42 and $59 to related party)
Total current liabilities
Long-term liabilities:
Operating lease liabilities (including $0 and $42 … to related party)
Total long-term liabilities
Total liabilities
Commitments and contingencies
Stockholders’ equity:
Common stock $0.001 par value
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
of operating lease liabilities (including $57 and $59 respectively, to related party)
Total current liabilities
Long-term liabilities:
Operating lease
8-K
EX-99.1
1owy7 3tt2db
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
8-K
EX-99.1
bun j5vo3gzn2
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-99.1
godya4k
24 Apr 23
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors
8:13am
8-K
EX-99.1
7uxk1e
10 Apr 23
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
8:30am
8-K
EX-99.1
cbe9jr
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am
8-K
EX-99.1
bkdnbelrxi x3
11 May 22
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
8:30am
8-K
EX-99.1
qoxgc0io pgg8mz0
23 Mar 22
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
4:05pm
8-K
EX-99.1
ik7uys71d3y3tq hqx
15 Nov 21
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development
8:00am